durvalumab,tremelimumab
astrazeneca,pfizer
['poseidon', 'lcsm,(-blcsm)', 'durva', 'nsclc', 'sclc', 'tremelimumab']
 4-years update on poseidon. durvalumab +/- tremelimumab +
chemotherapy in 1l metastatic
nsclc. 4y landmark survival: d+t+chemo: 21% vs 8% d+chemo: 16% vs 8% most of the improvement seen in non-squamous histology and krasmut #esmo22 #lcsm 
Medical Oncology ?? HGU Gregorio Marañón?@myESMO Faculty ?? Lung Cancer - Mesothelioma - Thymoma?Power to the patients #endlungcancer #lcsm